NCT01055938CompletedPhase 1
An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fasting Conditions.
Dr. Reddy's Laboratories Limited1 site in 1 country34 target enrollmentStarted: December 2006Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Bioequivalence study of Dr.Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg
Study Overview
Brief Summary
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study of Divalproex Sodium coated particles in capsules 125 mg with Depakote® Sprinkle125 mg capsules in healthy, adult, human subjects under fasting conditions.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study of Divalproex Sodium Capsules (Sprinkle), 125 mg of Dr.Reddy's Laboratories Limited,comparing with that of Depakote® Sprinkle 125 mg capsules of Abbott Laboratories, USA in healthy, adult, human subjects under fasting conditions with an adequate washout period of 10 days.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects must fulfill all of the following criteria to be considered for inclusion into this study:
- •Subjects who will provide written informed consent.
- •Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive) weighing at least 50 kg.
- •Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2
- •Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study.
- •Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance.
- •Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent. -
Exclusion Criteria
- •The subjects will be excluded based on the following criteria during screening and during the study
- •Subjects incapable of understanding the informed consent.
- •Subjects who have:
- •Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg
- •Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator.
- •Pulse rate below 50/min or above 100/min.
- •History of hypersensitivity or idiosyncratic reaction to Investigational drug products or any other related drugs.
- •Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- •Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study.
- •Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period.
- •Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing.
- •Subj eets who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
- •Subjects with clinically significant abnormalities (such as Laboratory Findings,ECG, X-Ray, Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, HCV, Syphilis, Hepatitis B etc.,).
- •Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.
Arms & Interventions
Divalproex Sodium
Experimental
Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Intervention: Divalproex Sodium (Drug)
Depakote Sprinkle
Active Comparator
Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
Intervention: Divalproex Sodium (Drug)
Outcomes
Primary Outcomes
Bioequivalence study of Dr.Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg
Time Frame: 4 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)HealthyNCT01132183Dr. Reddy's Laboratories Limited34
Completed
Phase 1
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed ConditionHealthyNCT01056627Dr. Reddy's Laboratories Limited34
Completed
Phase 1
Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting ConditionsHealthyNCT02322619Dr. Reddy's Laboratories Limited26
Completed
Phase 1
Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed ConditionsHealthyNCT01513057Dr. Reddy's Laboratories Limited61
Completed
Phase 1
Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting ConditionsHealthyNCT01513044Dr. Reddy's Laboratories Limited68